Baudax Bio, Inc. BXRXQ
—
0.00
0.00
NaN
as of 25 Sep
- Market cap
- —
- P/E
- 0.0×
Follow BXRXQ
Growth Flags
show if company had growth for consecutive years
| Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
1.06 | 15.63 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(0.08) | (1.33) | (1.29) | — |
P/B ratio |
0.00 | 1.28 | 0.00 | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — |
EV/Sales |
2.79 | 8.81 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.03 | — |
EV/Operating CF |
(0.11) | (0.19) | 0.05 | — |
EV/FCF |
(0.11) | (0.19) | 0.05 | — |
Quick Ratio |
0.26 | 1.05 | 1.68 | 2.30 |
Current Ratio |
0.30 | 1.50 | 2.03 | 2.61 |
Net Debt/EBITDA |
(0.03) | 0.45 | 0.29 | 0.55 |
Debt/Assets |
70.96% | 16.01% | 13.32% | 0.00% |
Debt/Equity |
(0.29) | 0.65 | (0.62) | 0.00 |
Asset Turnover |
0.04 | 0.02 | 0.01 | — |
Operating CF/Net income |
0.47 | 2.49 | 0.58 | 1.54 |
Capex/Depreciation |
(0.01) | (0.07) | (0.25) | (2.75) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 |
| 1,067.45% | 2,513.54% | 482.87% | 0.00% | |
| (185.74%) | (32.41%) | (123.79%) | 0.00% | |
ROIC |
0.00% | (202.50%) | 0.00% | 0.00% |
Return on Tangible Assets |
408.04% | (153.69%) | (321.91%) | (188.81%) |
Average Days of Receivables |
96.36 | 183.18 | 37.76 | — |
Research and Development Expense of Revenue |
306.30% | 289.35% | 1,843.20% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,900.63% | 4,195.37% | 8,790.06% | 0.00% |
Intangible Assets out of Total Assets |
0.21 | 0.45 | 0.38 | 0.53 |
Share Based Compensation of Revenue |
110.40% | 443.43% | 1,894.73% | 0.00% |
Graham Net Nets |
(24.31) | (0.98) | (2.49) | — |
Graham Number |
678.16 | 0.00 | 11,951.18 | — |
Earnings Yield |
(8,090.46%) | (159.89%) | (403.46%) | — |
Free Cash Flow Yield |
(2,432.53%) | (293.11%) | (244.68%) | — |
Revenue per Share |
3.82 | 19.64 | 37.07 | 0.00 |
Operating CF per Share |
(83.71) | (895.82) | (3,312.63) | (7,469.25) |
Capex per Share |
(0.06) | (3.69) | (48.05) | (196.87) |
Free Cash Flow per Share |
(83.77) | (899.51) | (3,360.68) | (7,666.12) |
Cash per Share |
15.84 | 288.93 | 2,281.35 | 2,647.76 |
Shareholders Equity per Share |
(73.02) | 240.47 | (1,112.71) | (2,495.67) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(73.02) | 240.47 | (1,112.71) | (2,495.67) |
Free Cash Flow |
(27.81) | (49.47) | (44.70) | (51.36) |
Working Capital |
(15.11) | 7.85 | 18.59 | 12.42 |
Capital Expenditures |
(0.02) | (0.20) | (0.64) | (1.32) |
Net Current Asset Value |
(27.93) | (16.56) | (46.81) | (50.80) |
EV/EBIT |
0.00 | 0.00 | 0.03 | — |
Capex to Sales |
0.02 | 0.19 | 1.30 | 0.00 |
Net Profit Margin |
(4,633.18%) | (1,830.46%) | (15,436.11%) | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — |
| Other line items | ||||
Depreciation/Fixed assets |
3.07 | 0.56 | 0.51 | 0.10 |
Cash ROIC |
240.20% | (144.19%) | (198.87%) | (5,384.20%) |
Accounts Receivable Turnover |
2.89 | 3.64 | 0.00 | — |
Accounts Payable Turnover |
2.60 | 0.95 | 0.88 | — |
Inventory Turnover |
0.00 | 0.61 | 0.00 | — |
Average Days of Payables |
204.50 | 219.15 | 769.83 | 0.00 |
Days of Inventory on Hand |
0.00 | 746.72 | 627.58 | — |
Average Receivables |
0.44 | 0.30 | — | — |
Average Payables |
2.70 | 2.56 | 1.96 | — |
Average Inventory |
— | 3.99 | — | — |
Average Assets |
31.65 | 61.01 | 61.47 | — |
Average Common Equity |
(5.51) | (0.79) | (15.76) | — |
Columns are period end dates